A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 3 of 3 changed
See other at-risk trials from DEM BioPharma, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date pushed from Sep 2026 to Oct 2026
    • Study sites: 0 to 1
  2. Primary endpoint(s) modified
    • Secondary endpoints revised (11)
    • Study description shortened, about 4 words
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a first-in-human Phase 1 study of DEM301 in adults with previously treated advanced metastatic colorectal cancer. DEM301 is an investigational antibody-drug conjugate. The study will evaluate the safety and tolerability of DEM301, identify doses for further study, and assess how the drug behaves in the body and whether it shows signs of activity against the cancer.
Trial Details
NCT Number NCT07805369
Lead Sponsor DEM BioPharma, Inc.
Conditions
(from sponsor)		 Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Related terms Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov